The Impact of Prenatal Magnesium on Offspring's Neurodevelopment
A randomized clinical trial involving 1433 pregnant individuals at risk of preterm delivery and their 1679 infants found that intravenous magnesium sulfate administered between 30 and 34 weeks' gestation did not significantly reduce the risk of death or cerebral palsy in the children at 2 years of age. While the study showed that magnesium sulfate did not increase the chance of child survival without cerebral palsy, it had limited power to detect small differences between the groups.